Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Published byJasper Park Modified over 5 years ago

Similar presentations

Presentation on theme: "Ceritinib is a potent ALK inhibitor in crizotinib-naïve models."— Presentation transcript:

1 Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.
Ceritinib is a potent ALK inhibitor in crizotinib-naïve models. A and B, cell survival assay of H3122 (A) and H2228 (B) cells treated with the indicated doses of crizotinib or ceritinib for 72 hours. Cell survival was assayed by CellTiter-Glo. C and D, H3122 (C) and H2228 (D) cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. E, SCID beige bearing H2228 cells were administered crizotinib or ceritinib orally once daily for 14 days. The arrow indicates when treatments were stopped, and tumor growth was monitored in animals up to 4 months. Tumor volumes, mean ± SD (n = 8). p, phosphorylated. Luc Friboulet et al. Cancer Discovery 2014;4: ©2014 by American Association for Cancer Research

Download ppt "Ceritinib is a potent ALK inhibitor in crizotinib-naïve models."

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.
CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
Volume 19, Issue 5, Pages (May 2011)

Volume 19, Issue 5, Pages (May 2011)
by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K

by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K
Volume 28, Issue 1, Pages (July 2015)

Volume 28, Issue 1, Pages (July 2015)
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors  Hsin-Yi Wang, MD  Journal of Thoracic.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors  Hsin-Yi Wang, MD  Journal of Thoracic.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
NF1 downregulation activates MAPK pathway signaling.

NF1 downregulation activates MAPK pathway signaling.
Educational Objectives

Educational Objectives

Similar presentations

Ads by Google